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Abstract
Background. The median survival for patients with glioblastoma (GBM), the most common primary malignant brain
tumor in adults, has remained approximately 1 year for more than 2 decades. Recent advances in the field have identified
GBM as a sexually dimorphic disease. It is less prevalent in females and they have better survival compared to males.
The molecular mechanism of this difference has not yet been established. Iron is essential for many biological processes
supporting tumor growth and its regulation is impacted by sex. Therefore, we interrogated the expression of a key component of cellular iron regulation, the HFE (homeostatic iron regulatory) gene, on sexually dimorphic survival in GBM.
Methods. We analyzed TCGA microarray gene expression and clinical data of all primary GBM patients (IDH-wild
type) to compare tumor mRNA expression of HFE with overall survival, stratified by sex.
Results. In low HFE expressing tumors (below median expression, n = 220), survival is modulated by both sex and MGMT
status, with the combination of female sex and MGMT methylation resulting in over a 10-month survival advantage (P <
.0001) over the other groups. Alternatively, expression of HFE above the median (high HFE, n = 240) is associated with significantly worse overall survival in GBM, regardless of MGMT methylation status or patient sex. Gene expression analysis
uncovered a correlation between high HFE expression and expression of genes associated with immune function.
Conclusions. The level of HFE expression in GBM has a sexually dimorphic impact on survival. Whereas HFE expression below the median imparts a survival benefit to females, high HFE expression is associated with significantly worse overall survival regardless of established prognostic factors such as sex or MGMT methylation.

Key Points
• There is a sex-specific effect of HFE mRNA expression in GBMs on survival.
• High HFE results in poor survival in GBM regardless of patient sex or MGMT status.
• Survival differences may be due to HFE related immunosuppression in the tumor
microenvironment.
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Importance of Study
Expression of the homeostatic iron-regulatory
gene, HFE, is a novel prognostic indicator of
survival for brain tumors. These data further
support the sexually dimorphic nature of glioblastoma and, given the importance of HFE

HFE gene expression resulted in a 5-year decrease in patient survival compared to low HFE expression.25
Here we present data revealing that there are significant sex differences in overall survival associated with HFE
gene expression and that a synergistic interplay exists between MGMT methylation status, sex, and HFE expression
that impact patient survival in GBM.

Methods
HFE mRNA Expression and Survival Data
Gene expression, tumor phenotype, and de-identified patient data were acquired from The Cancer Genome Atlas
(TCGA) GBM (n = 525). This dataset was downloaded
from a publicly available data visualization software program, GlioVis.26 Microarray data were chosen for its large
sample size (n = 525) and availability of data including
sex, survival status, and tumor MGMT methylation
status. Updated survival data for TCGA GBM were contributed by Dr Joshua B. Rubin’s group. To identify and
remove outliers, Cook’s distance was calculated based
on a linear regression of survival times with respect to
HFE mRNA expression. Any observation with Cook’s distance greater than 98th percentile was noted as an outlier
and removed from data analysis (n = 10). We excluded
nonprimary tumors (n = 21) and IDH-mutant samples
(n = 34) from the analysis group resulting in 460 total
samples for analysis.
We first determined the median HFE mRNA expression
of all GBM samples to establish the high and low HFE
groups. We then focused our analysis on primary, IDH-WT
tumors (n = 460, low n = 220, high n = 240). To determine
whether the impact of HFE on survival may be therapy
dependent, we compared individuals who had received
temozolomide (TMZ) (n = 274) versus those who did not
(n = 170). Positive TMZ therapy was defined by any patient who had TMZ therapy, in combination with any other
therapy, for example, concomitant radiation therapy. See
Table 1 for demographics summary.
We attempted to replicate our main results in other
datasets but to appropriately assess our model, we needed
to identify datasets that contained all of the variables used
in the original model, which includes survival time, sex,
MGMT methylation status, and recurrence status, in addition to the gene expression profiles of the tumors. At least
one of these main variables was missing from each of the
available datasets except for the Murat dataset (although
this did not include IDH status).
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Glioblastoma (GBM) is the most common type of primary malignant brain tumor in adults. Despite aggressive
therapy, the median survival for GBM patients has remained
at about 1 year, necessitating the need for a new paradigm
to GBM treatment.1,2 Recent evidence suggests that GBM
is a sexually dimorphic disease.3,4 GBMs are less common
in females, yet females have better survival.5,6 Prognostic
indicators like O[6]-methylguanine-DNA methyltransferase
(MGMT) and Isocitrate Dehydrogenase (IDH) status also
modify survival based on sex. Females with MGMT methylated GBMs have better survival rates than males and males
have improved survival with IDH-mutant GBMs.7,8 The molecular mechanism that underlies this sex-based difference
has yet to be established.
Iron homeostasis is essential for cellular energy production and DNA synthesis, particularly in rapidly dividing
cells, and thus plays a critical role in cancer development and maintenance.9–11 Elevated expression of ironregulating genes is correlated with worse survival in
multiple cancers including breast, prostate, and colon.10–14
In breast cancer, a molecular signature representing decreased iron acquisition is associated with better outcome
whereas a signature indicating decreased iron export is associated with worse outcome.15 In GBMs, both glioma and
cancer stem cells can upregulate the iron transporter transferrin, conferring improved iron extraction from the tumor
microenvironment to promote proliferation.16,17
A key regulator of cellular iron uptake is the homeostatic
iron-regulator protein (HFE), which binds to transferrin receptors (TFRs) decreasing TFR affinity to transferrin, consequently reducing iron uptake. Mutations of the HFE gene
result in cellular iron overload, and one of the mutations
C282Y was first discovered as the genetic cause of an iron
overload disorder found predominantly in men; hemochromatosis.18 To date, the role of HFE in tumor biology has
focused primarily on the impact of HFE mutations.19–23 For
example, we have previously shown female GBM patients
who carry C282Y HFE polymorphism have shorter survival
than both wild-type (WT) patients and male metastatic
brain tumor patients with C282Y23.23
Despite the interest in the incidence and effect of
common HFE gene mutations on the disease, including
cancer, very little data have been published on the impact
of expression of WT HFE gene levels in cancer. Reuben
et al.24 previously described higher levels of HFE expression in tumor cell lines from melanoma, lung, and kidney
cancers, yet few studies have looked at HFE expression in
patient tumor samples. We previously identified several
iron metabolism genes associated with changes in survival
for patients with low-grade glioma (LGG) and found high

in regulating cellular iron uptake, may provide
molecular indicators to focus interrogation of
the biological basis for the sex-dependent outcomes. Moreover, the gene expression profiles
support the role of HFE as both influencing the
immune system and iron biology of the tumor
microenvironment.
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Demographics of GBM Patients Included in the Study

Sex
MGMT (n = 301)

Overall (n = 460)

High HFE (n = 240)

Low HFE (n = 220)

Female, % (n)

61.52 (283)

58.75 (141)

64.55 (142)

Male, % (n)

38.48 (177)

41.25 (99)

35.45 (78)

Methylated, % (n)

42.52 (128)

41.33 (62)

43.71 (66)

Unmethylated, % (n)

57.48 (173)

58.67 (88)

56.29 (85)

Median (range)

KPS

Median (range)

Resection (n = 457)

Biopsy, % (n)

12.25 (56)

11.76 (28)

12.79 (28)

Tumor resection, % (n)

87.75 (401)

88.24 (210)

87.21 (191)

No, % (n)

38.29 (170)

39.47 (90)

37.04 (80)

Yes, % (n)

61.71 (274)

60.53 (138)

62.96 (136)

TMZ (n = 444)

61 (10–89)
80 (20–100)

60 (14–86)
80 (20–100)

.76

61 (10–89)

.62

80 (20–100)

.83
.85
.67

TMZ, temozolomide; GBM, glioblastoma.
Two-sample test for equality of proportions was used for sex, MGMT, resection, and TMZ and Welch two-sample t-test was used for age and
KPS. Median HFE mRNA expression was based on all GBM patients provided by TCGA GBM, including IDH-mutant, nonprimary, and outlier samples (determined by Cook’s distance). Removal of those samples results in an n = 20 difference in HFE groups, as opposed to n = 230 equal split
as would otherwise be expected. Not all phenotype data are available for each sample, thus the number of available samples are included next to
category name.

  
Statistical Analysis

Gene Expression Analysis

Sample test for equality of proportions was used to detect baseline differences for sex, MGMT, resection, and
TMZ and Welch two-sample t-test was used for comparison of age and Karnofsky Performance Score (KPS).
Data analysis was performed in R (v 3.5.1). Kaplan–Meier
survival curves were plotted to characterize survival
differences and P-values were generated using logrank test. From R package “survival,” Cox Proportional
Hazard (CoxPH) models were used to control for sex,
age, MGMT methylation status, KPS, and resection. For
overall model fit, P-values were based on robustified variance estimates (known as Huber sandwich estimator).27
We further confirmed results using Weibull Accelerated
Failure Time model, to ensure the results hold true even
in the absence of non-proportionality of hazards.28 For
all analyses, two-tailed P-values less than .05 were considered statistically significant.

The aim of our gene expression analysis was to identify
gene sets which were significantly different between low
and high HFE groups and subsequently, the expression of
which also correlated with HFE mRNA expression. Herein,
we only focused on 2 subsets of gene expressions that
were shown to have the greatest survival differences between low and high HFE while also presenting comparative
information on sex differences: males with MGMT methylated tumors and females with MGMT methylated tumors.
Genes found to be most different between the 2 groups
were then analyzed through PANTHER GO Enrichment
Analysis of Biological mechanisms.29
We followed a similar strategy described below for each
of the subsets.

Microarray Data Processing by GlioVis
HFE mRNA expression was reported by microarray data
collected from the Affymetrix expression array HG-U133
platform. GlioVis downloaded available raw.CEL files from
TCGA and processed in R using the Bioconductor suite.
The “affy” package was used for robust multi-array average normalization followed by quantile normalization.
The median of all probes was used for genes with several
probe sets.
GlioVis provided mRNA data on approximately 12 000
genes analyzed in each GBM tumor sample. These data
were downloaded and analyzed as described in Gene
Expression Analysis section. To elucidate the meaning of
differential gene expression, gene sets were analyzed by
GO Enrichment Analysis.

(1) First, we conducted nearly 12 700 univariate robust
linear regressions (R package MASS) where the response was high versus low HFE group and the gene
expression values were the predictors. False discovery rate (FDR) adjusted P-values were calculated
to correct for multiple testing errors. We chose those
genes which had FDR adjusted P-values less than
.05, therefore this set of genes had expressions that
differ significantly between high versus low HFE.
(2) Next, we calculated the simple Pearson correlation
coefficient between HFE expression and the gene
expressions obtained from step (1). We choose only
those genes whose correlations are statistically significant after controlling the P-values by FDR adjustment. The level of significance for these adjusted
P-values is set at .05.
(3) In a more realistic scenario, one needs to find the association between HFE expression and all the other significant gene expressions from step (1) put together as
multivariate covariates. This mimics how one gene is
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associated with HFE in the presence of several other
genes. We conducted penalized elastic net regression
(R package glmnet) with HFE expression as response
and the gene expressions from step (1) as covariates.
The elastic net model had a considerable higher weight
for ridge regression than LASSO so that the number
of resulting genes were not over-regularized. This regression controls the problem of multicollinearity by
shrinking the coefficients of highly correlated gene
expressions. We chose only those genes whose coefficients are non-zero, implying an association with HFE.

Results
High HFE Expression Is Associated With
Significantly Worse Patient Survival in
Brain Tumors
In the TCGA GBM LGG microarray dataset, tumors
expressing HFE above the median are associated

A
100%

B

50%

HFE High (n=242, events=213, median=12.9)
HFE Low (n=255, events=207, median=14)

75%
Surviving

HR = 0.2, (0.15 – 0.27)
*** Log-rank p value = 0
*** Wilcoxon p value = 0

Glioblastoma
100%

HFE High (n=331, events=184, median=21.3)
HFE Low (n=336, events=55, median=114.1)

75%
Surviving

  

All Brain Tumors

HR = 0.77, (0.64 – 0.94)
** Log-rank p value = 0.0088
** Wilcoxon p value = 0.0322

50%
25%

25%

0%

0%
0

50

100

150

200

0

50
100
Survival time (Months)

Survival time (Months)

D
mRNA expression (log2)

Tumor Grade
7.5

5.0

2.5

II

III

E

Tumor Histology

mRNA expression (log2)

C

7.5

5.0

2.5

IV
Oligodendroglioma

Oligoastr- Astrocytoma
ocytoma

GBM

GBM Subtype
5.5
5.0
4.5
4.0
Classical Mesen- Proneural
chymal

Figure 1. (A–E) Survival and expression differences of HFE in low-grade gliomas and glioblastoma. Survival in low HFE (blue) versus high HFE
(red) in all brain tumors (A) and in glioblastoma (B). HFE mRNA expression based on tumor grade (C), tumor histology (D), and glioblastoma subtype (E). These figures were directly rendered by and downloaded from GlioVis.
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with shortened survival for all brain tumor populations (114 months vs 21.3 months, log-rank P < .0001,
Figure 1A). Restricting the analysis to the TCGA GBM
data also revealed a similar and significant difference (Figure 1B; P = .0088) between the high and low
HFE GBM expressing groups. HFE expression increases with increasing grade of the tumor (all adjusted P < .05, Figure 1C) and is the highest in GBM
(P < .0001, Figure 1D). Furthermore, within GBM
subtypes, HFE expression is highest in the mesenchymal subtype, associated with worse patient
prognosis, and lowest in the proneural subtype
(P < .0001, Figure 1E).
A CoxPH regression model was then run with HFE as
a continuous variable. After controlling for known prognostic factors (sex, MGMT status, KPS, resection, and
age), the impact of HFE on survival was not significant,
yet neither was KPS, resection, sex, nor MGMT methylation status (Table 2 and Supplementary Table S1).
Because MGMT and sex have been established as significant prognostic indicators, this was an unexpected
finding. Thus, we considered whether HFE, MGMT
status, and sex may interact, suggesting that HFE expression might be negatively influencing survival based
on the patient’s sex and MGMT methylation status. To
nullify the possibility of confounding of HFE expression
by sex and MGMT methylation status, a simple linear regression was performed, verifying HFE expression did

The final set of genes are both common to genes obtained
from step (2) and step (3). Note that this multilevel strategy
was stricter and controlled for spuriously correlated gene
expressions. Please see Figure 3 for schematic and results
of this analysis strategy.

mRNA expression (log2)
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Sex

MGMT

Sex and MGMT
(All therapy)

Temozolomide
Therapy

173

Unmethylated

62

112

61

Female: Methylated

Male: Unmethylated

Female: Unmethylated

81

38

Male: Unmethylated

Female: Unmethylated

6.6 (4.6–17.5)

  

.0008***

.0002***

.002**

.001**

.12

.002**

.06

16

5.8 (1.6–10.6)

6.6 (3.6–25.4)

P

.049*

.8

.06

Female: Unmethylated

14
23

3.1 (2.0–7.6)

14.5 (10.2–21.9)

12.9 (12.2–14.9)

20.7 (15.6–26.9)

16.5 (13.3–20.8)

11.7 (9.9–17.5)

12.6 (10.6–14.0)

17.8 (13.8–21.3)

13.3 (10.7–17.6)

12.2 (10.7–14.0)

15.3 (12.9–17.8)

12.5 (10.5–15.3)

CoxPHb

20

Male: Unmethylated

17

27

60

28

38

45

87

45

55

132

100

142

Log rank

15

27

Female: Methylated

Male: Methylated

CoxPH

b

18

43

Female: Methylated

Log rank

47

Male: Methylated

CoxPH

b

Log rank

66

Male: Methylated

CoxPH

a

Log rank

128

Methylated

CoxPHa

Log rank

177

Female

12.7 (11.9–14.0)

Median (CI)

8

16

5

9

18

40

19

31

28

57

26

40

85

66

78

142

7

13

4

9

13

31

14

26

21

45

19

35

66

54

62

120

Deaths

6.1 (4.1-NA)

7.6 (1.1-NA)

15.1 (3.6-NA)

2.0 (1.1-NA)

11.7 (9.9-NA)

12.7 (11.3–15.4)

25.7 (19.9-NA)

16.1 (12.7–21.1)

11.7 (9.9–22.2)

10.9 (9.5–14.0)

24.9 (17.8–33.2)

13.3 (10.2–19.5)

11.5 (10.1–13.3)

16.9 (13.8–21.2)

14.7 (11.5–20.1)

12.6 (10.9–13.9)

Median (CI)

N

242

Deaths

N

283

Male

Low HFE mRNA (<Median)

All Data

.07

.03*

.05

.0002***

<.0001****

<.0001****

<.0001****

.014*

.002**

.003**

P

Deaths
122
80

46
66

20
26
42
24

12
14
29
14

8
10
10
9

N
141
99

62
88

26
36
55
33

16
24
41
19

9
10
11
12

9.1 (2.9-NA)

5.3 (1.6-NA)

5.5 (2.3-NA)

5.9 (2.8-NA)

14.9 (12.2-NA)

13.9 (12.6–16.6)

15.6 (12.4-NA)

18.1 (12.9-NA)

12.2 (8.8–17.9)

12.9 (11.9–15.0)

13.6 (7.0–20.7)

12.9 (7.6–20.4)

12.9 (10.8–14.9)

13.6 (10.7–18.1)

10.7 (8.6–14.9)

12.9 (11.9–14.9)

Median (CI)

High HFE mRNA (≥Median)
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NA, upper confidence interval could not be calculated/infinity.
aCoxPH P-value based on hazard coefficients.
bRobustified CoxPH P-value for the overall model fit.
*P-value < .05, **P-value < .01, ***P-value < .001, ****P-value < .0001.

No Temozolomide
Therapy

Survival Differences Based on HFE Group, MGMT Status, Sex, and Temozolomide Therapy

.8

.7

.6

.2

.3

.7

.6

.4

.7

.1

P
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Table S2). Furthermore, interrogation of the Murat data
using the median HFE expression generated similar results
(Supplementary Table 3).

not differ significantly based on sex or MGMT status
(Table 1).

High HFE Expression Abrogates Survival Benefit
of Both Female Sex and MGMT Methylation

High HFE Negates the Impact of MGMT
Methylation in TMZ Treatment

Male (12.6, n = 142)
Female (14.7, n = 78)
Log Rank p = 0.07
CoxPh p = 0.003**

50

0

10

20

30

40

50

Log Rank p = 0.002**
CoxPh p = 0.014*
50

0

60

0

10

Survival (months)

40

50

Percent survival

Log Rank p = 0.1
CoxPh p = 0.7
50

10

20

30

40

Survival (months)

0

10

50

60

30

40

50

60

F
100

Log Rank p = 0.4
CoxPh p = 0.6
50

0

20

Survival (months)

Methylated
(13.6, n = 62)
Unmethylated (12.9, n = 88)

100

Male (12.9, n = 141)
Female (10.7, n = 99)

0

0

(13.3, n = 40)
(24.9 n = 26)
(10.9 n = 57)
(11.7 n = 28)

Log Rank p = <0.0001****
CoxPh p = <0.0001****

50

60

E

100

0

30

Male, Methylated
Female, Methylated
Male, Unmethylated
Female, Unmethylated

Survival (months)

D

High
HFE

20

Sex and MGMT

100

Methylated
(16.9, n = 66)
Unmethylated (11.5, n = 85)

Percent survival

0

C

MGMT

100
Percent survival

Low
HFE

Percent survival

100

  

B

Sex

Percent survival

A

We confirmed that irrespective of HFE status, sex, and
methylation status, receiving TMZ therapy versus treatments without TMZ (but did receive radiation) was beneficial for survival. Supporting our previous results, for
patients taking TMZ, the survival advantage of being female is amplified by positive methylation status in the
low HFE group (25.7 months vs 16.1 months in methylated
males, Table 2). Regardless of MGMT status or sex, high
HFE continued to abrogate survival advantages seen at
low HFE (Table 2).
In patients who did not receive TMZ, we observed the
same pattern of sex-based survival differences, with females having a survival advantage over males at low HFE
and similar survival to males at high HFE (Table 2). At low
HFE, the median survival of females in the methylated
group was 15 months versus 2 months for males in the
same group. Similarly, to the group treated with TMZ, high
HFE expression negated the survival benefit of the combination of female sex and methylation status in the group
that was not treated with TMZ (Table 2).

0

10

20

30

40

Survival (months)

50

60

(12.9, n = 26)
Male, Methylated
Female, Methylated (13.6, n = 36)
(12.9 n = 55)
Male, Unmethylated
Female, Unmethylated (12.2 n = 33)
Log Rank p = 0.4
CoxPh p = 0.6

50

0

0

10

20

30

40

50

60

Survival (months)

Figure 2. (A–F) Impact of HFE expression, sex, and MGMT status on survival in glioblastoma. The top row represents all samples with low HFE
expression (below median) and is separated into 3 columns based on differences in survival in males versus females (A), MGMT status (B), or
both sex and MGMT status (C). Similarly, the row below is also separated by the same comparisons as above yet representing individuals with
high HFE expression (D–F).
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The dataset was then divided into 2 separate groups, low
HFE and high HFE based on median HFE expression. CoxPH
analysis of these groups, controlling for the same factors as
mentioned above, revealed 2 distinct and sexually dimorphic
survival patterns. A low HFE tumor expression level is associated with better survival for females (Figure 2A) compared to
males but there is no sex difference in survival in the high HFE
tumor expressing group (Figure 2D). The established MGMT
tumor methylation survival benefit was seen in the low HFE
group, but not in the high expressing HFE group (Figure 2B
and E). There was a clear effect of sex and HFE status on the
MGMT effect; females with low HFE and MGMT methylated
tumors survive significantly longer than males regardless of
their MGMT status. High HFE expression negated the MGMT
and sex benefits to survival (Figure 2C and F).
We determined to use the median HFE expression to
help maintain equal sample sizes for the analysis groups
(low HFE vs high HFE) to prevent imbalance in the groups.
To confirm that impact of HFE on survival does not depend
on the chosen median cutoff, we reproduced our main result using 40th and 60th percentile cutoffs (Supplementary

Percent survival
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Figure 3. Gene expression analysis of low versus high HFE gene expression with the number of genes found at each stage of analysis. The
number of genes upregulated in low HFE and in high HFE states, separated by sex. The number of genes from the analysis of low versus high HFE
expression genes in females is depicted in magenta, while those of males are depicted in blue. Gene analysis focused on individuals with positive
MGMT methylation since the greatest sex-based survival difference was seen between males and females with MGMT positive methylation.
  

Gene Expression Profiles
To begin to interrogate the relationship between HFE expression and the tumor microenvironment, over 3000
genes were found to be significantly different in the low
and high HFE expressing groups (Figure 3) including sexbased differences. When comparing upregulated genes,
males and females shared 884 genes in the low HFE group
and 694 genes in the high HFE group (data not shown).
Gene enrichment analysis in low HFE groups shows
upregulation of genes responsible for DNA topological
change, synaptic vesicle assembly, and microtubule development (Figure 4A and B) in both sexes. A unique
pathway upregulated in males with low HFE includes negative regulation of histone H3-K9 methylation (Figure 4A).
Females in the low HFE group show unique upregulation
in nucleosome disassembly and response to hydroxyurea
(Figure 4B).
High HFE expression, regardless of sex, is associated
with upregulation of pathways involving T-cell activation,

chemokine production, and cell apoptosis, among others
(Figure 4C and D). Specifically, the most highly upregulated
genes in both males and females with high HFE were those
associated with the regulation of CD4-positive, T-cell proliferation (Figure 4C and D). Males with high HFE showed
enrichment for genes associated with positive regulation
of antigen presentation and processing (Figure 4C), while
females uniquely showed upregulation of pathways associated with ganglioside catabolic processes and AMP biosynthesis (Figure 4D).

Discussion
We present data showing that the level of gene expression of a key iron-regulating protein, HFE, is a prognostic indicator of survival in patients with brain tumors.
Furthermore, in GBMs, the prognostic value of HFE is impacted by sex and MGMT methylation status. Not only
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Figure 4. (A–D) GO Enrichment results of genes differentially upregulated in low versus high HFE, as observed separately in both males and
females. The dot plots show the top 10 biological processes based on fold enrichment value (converted to log 2 scale). The sizes of the dots
indicate the number of genes upregulated in that group that are also present in that biological process. The colors of the dots represent FDR adjusted P-values (converted to negative log 10 scale). The top row represents pathways enriched based on genes which were most significantly
upregulated at low HFE, while the bottom row represents pathways of genes upregulated in high HFE. The columns represent sex of individuals
in analysis (males on the left, females on the right). Thus, pathways upregulated in low HFE in males (A) and females (B) and those upregulated in
high HFE in males (C) and females (D) are represented for comparison.
  

does HFE expression in tumors impact survival, but high
expression completely abrogates previously published
positive prognostic indicators, specifically female sex and
positive MGMT methylation.
Furthermore, these data support recently published
studies on the impact of sex differences in GBM, while also
providing a critical new lens of analysis further informing
those studies. For example, we show that female sex is an
advantage only when HFE expression levels are low.6,30
Moreover, this finding extends to MGMT methylated tumors where only females with low HFE expression and
methylated tumors experience a significant survival advantage. When HFE tumor expression is high, methylation no longer conferred a survival advantage to females.
In contrast, we did not find significant differences in male

survival based on HFE expression status. Had we not separated these HFE analyses by sex, the significant differences for the expression data would have been washed
out by the male survival data. There was is no additional
benefit of HFE expression level to the MGMT methylation
status and survival for males. These data are consistent
with reports that females have a more significant survival
benefit from MGMT methylation.7
Sex may also influence treatment response, with females responding better to the standard of care therapy,
including TMZ, and our analysis found similar trends.6 We
confirmed that in patients treated with TMZ, methylation
is advantageous to females, yet only when HFE levels are
low. In the high HFE group, MGMT methylation no longer
conferred a survival advantage to females who were
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Gene expression data acquired from tumor samples provide information not only on the neoplastic cells but also
on the infiltrating immune cells which are critical to tumor
proliferation. Macrophages make up the bulk of infiltrating
immune cells in GBMs and play a critical role in regulating
the tumor microenvironment.34–38 HFE is highly expressed
in macrophages and these cells are key regulators of
iron.39–41 Thus, HFE mRNA expression may be reflective of
the volume of these cells in the tumor.
HFE expression may also be directly influencing the
immune cell function in the tumor microenvironment.
Expression of HFE interferes with MHC class I antigen presentation and impairs activation and differentiation of CD8+
T lymphocytes.24,42–44 HFE’s role as a negative regulator
of CD8+ T cells may allow for the predominance of other
lymphocytes consistent with the significant upregulation
of CD4+ T-cell genes identified in the high HFE groups.
Finally, an obvious goal of identifying the sex-based
differences in GBMs prevalence and outcomes is to help

Conclusions
Expression of the iron-regulatory gene, HFE, is associated with sexually dimorphic survival in GBM patients.
Furthermore, at low expression, the survival effect is impacted by sex and MGMT methylation status. Conversely,
high HFE expression completely abrogates previously published positive prognostic indicators, specifically female
sex and positive MGMT methylation. The data support further investigation of characterizing the sex-dependent iron
signature of GBMs and suggest a relationship between
the immune system (including tumor-associated macrophages) and iron biology in the tumor microenvironment.

Supplementary Data
Supplementary data are available at Neuro-Oncology
online.
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develop models to guide therapeutic strategies. Although
our studies and others in this field are in their infancy, insights can begin to be discussed. For example, a developing therapeutic area for GBM has been immunotherapy,
specifically with regard to the use of PD-L1 inhibitors.
Binding of PD-1 to PD-L1 delivers a signal to encourage the
suppression of T-cell proliferation. Upregulation of PD-L1 in
circulating monocytes and tumor-associated macrophages
is associated with cytotoxicity toT cells, while also inducing
and maintaining T regulatory cells (CD4 T cells) in glioma
with increased expansion, perhaps to maintain immunosuppressive environment through T regulatory cells in the
tumor, which is ultimately associated with worse GBM
prognosis.45–47 Interestingly, this finding is consistent with
observations in the high HFE groups, both in males and females; an upregulation of genes involved in T-cell proliferation and activation.48 PD-L1 expression is higher in IDH-WT
glioma and higher in higher grade tumors, which seems
to follow the same pattern as HFE expression (higher in
IDH-WT and GBM). Both mechanisms may be related, and
if so, may help explain the discrepancies seen between
studies in PD-L1 inhibitor efficacy, as only half of all GBM
patients would potentially benefit from PD-L1 inhibitors.49
This is an example of how the use of HFE status of GBMs
in clinical settings may prove to be useful in identifying patients who are likely to benefit from PD-L1 inhibitors.
Lastly, in contrast to our findings in GBMs, high HFE
expression in breast cancer tumors was associated with
better survival in an all-female study. Despite the differences in our findings, these studies underscore the key
role of HFE gene expression in predicting survival but indicate that the results are sex- and cancer specific.

Neuro-Oncology
Advances

treated with TMZ. Because HFE status was determined by
the median mRNA expression of all GBM patient tumor
samples, our data predict that half of all females with
GBM would not have the anticipated better survival due to
MGMT methylation. In the TMZ group, survival differences
widened slightly. Females at low HFE and MGMT methylated tumors have a median survival of 25.7 months, which
is close to twice the median survival of patients with GBM
overall. These data support results by Yang et al.,30 yet,
with the caveat that females had improved response to
TMZ only if their HFE expression was lower than the median, otherwise, it was similar to males. From these data,
it can be postulated that HFE is either actively modulating response to TMZ or is a marker of response to TMZ
therapy. However, even those females who do not receive
TMZ therapy still experience the greatest survival advantage when their tumors have the combination of MGMT
methylation and low HFE expression. The effects of HFE
in the tumor microenvironment do not simply reflect sexbased levels of HFE expression in the tumors (Table 2).
Thus, the HFE survival effect appears to be intrinsic to
the tumor microenvironment. The underlying mechanism
is currently being explored but could be related to epigenetic influences. For example, iron is a required co-factor
for demethylases,31 thus its availability directly impacts on
histone and DNA methylation, and consequently on gene
expression. Iron overload dysregulates global methylation
and mice with HFE mutations have lower rates of global
methylation than WT mice.32 Likewise, iron chelation also
results in epigenetic alterations in breast cancer cells
making them more susceptible to doxorubicin and cisplatin.33 These data link HFE expression, which regulates
cellular iron status, to methylation state. This information
could have clinical value. For example, the gene expression data showing the upregulation of topoisomerase
genes in both male and female low HFE groups suggests
that these tumors could be more susceptible to topoisomerase inhibitors.
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